Termination Letter from MEI Pharma, Inc. to Infinity Pharmaceuticals, Inc., dated July 23, 2023

EX-10.1 2 d442693dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

July 23, 2023


Infinity Pharmaceuticals, Inc.

1100 Massachusetts Avenue, Floor 4

Cambridge, Massachusetts 02138

Attention: General Counsel

Email: ***@***



Termination Notice

Dear Seth:

Reference is hereby made to that certain Agreement and Plan of Merger, dated as of February 22, 2023, by and among Infinity Pharmaceuticals, Inc. (“Iris”), MEl Pharma, Inc. (“Meadow”) and Meadow Merger Sub, Inc. (the “Merger Agreement”). Capitalized terms used but not defined in this letter shall have the meaning ascribed to such terms in the Merger Agreement.

Meadow hereby provides Iris with notice that (i) the Meadow Stockholder Approval was not obtained at a meeting duly convened therefor or at any adjournment or postponement thereof at which a vote upon the Meadow Stock Issuance was taken and (ii) in accordance with Section 7.2(c) of the Merger Agreement, Meadow hereby terminates the Merger Agreement with immediate effect.

Should you have any questions regarding the notice provided herein, please contact Meadow’s counsel, Steven Navarro at ###-###-#### or ***@***.

[Signature on the next page]

By:   /s/ David Urso
Name:   David Urso
Title   President & Chief Executive Officer



WilmerHale LLP

60 State Street

Boston, MA 02109

Attention: Hal J. Leibowitz, Cynthia Mazareas and Michael Gilligan

Email: ***@***; ***@***;